2323 related articles for article (PubMed ID: 24123533)
1. Integrated hollow mesoporous silica nanoparticles for target drug/siRNA co-delivery.
Ma X; Zhao Y; Ng KW; Zhao Y
Chemistry; 2013 Nov; 19(46):15593-603. PubMed ID: 24123533
[TBL] [Abstract][Full Text] [Related]
2. The synergistic effect of hierarchical assemblies of siRNA and chemotherapeutic drugs co-delivered into hepatic cancer cells.
Cao N; Cheng D; Zou S; Ai H; Gao J; Shuai X
Biomaterials; 2011 Mar; 32(8):2222-32. PubMed ID: 21186059
[TBL] [Abstract][Full Text] [Related]
3. Redox-responsive mesoporous silica nanoparticles: a physiologically sensitive codelivery vehicle for siRNA and doxorubicin.
Ma X; Teh C; Zhang Q; Borah P; Choong C; Korzh V; Zhao Y
Antioxid Redox Signal; 2014 Aug; 21(5):707-22. PubMed ID: 23931896
[TBL] [Abstract][Full Text] [Related]
4. Natural gelatin capped mesoporous silica nanoparticles for intracellular acid-triggered drug delivery.
Zou Z; He D; He X; Wang K; Yang X; Qing Z; Zhou Q
Langmuir; 2013 Oct; 29(41):12804-10. PubMed ID: 24073830
[TBL] [Abstract][Full Text] [Related]
5. pH-responsive complexes using prefunctionalized polymers for synchronous delivery of doxorubicin and siRNA to cancer cells.
Dong DW; Xiang B; Gao W; Yang ZZ; Li JQ; Qi XR
Biomaterials; 2013 Jul; 34(20):4849-59. PubMed ID: 23541420
[TBL] [Abstract][Full Text] [Related]
6. Pulmonary Codelivery of Doxorubicin and siRNA by pH-Sensitive Nanoparticles for Therapy of Metastatic Lung Cancer.
Xu C; Wang P; Zhang J; Tian H; Park K; Chen X
Small; 2015 Sep; 11(34):4321-33. PubMed ID: 26136261
[TBL] [Abstract][Full Text] [Related]
7. Targeted anticancer prodrug with mesoporous silica nanoparticles as vehicles.
Fan J; Fang G; Wang X; Zeng F; Xiang Y; Wu S
Nanotechnology; 2011 Nov; 22(45):455102. PubMed ID: 22019849
[TBL] [Abstract][Full Text] [Related]
8. A pH-responsive mesoporous silica nanoparticles-based multi-drug delivery system for overcoming multi-drug resistance.
He Q; Gao Y; Zhang L; Zhang Z; Gao F; Ji X; Li Y; Shi J
Biomaterials; 2011 Oct; 32(30):7711-20. PubMed ID: 21816467
[TBL] [Abstract][Full Text] [Related]
9. A mesoporous silica nanoparticle--PEI--fusogenic peptide system for siRNA delivery in cancer therapy.
Li X; Chen Y; Wang M; Ma Y; Xia W; Gu H
Biomaterials; 2013 Jan; 34(4):1391-401. PubMed ID: 23164421
[TBL] [Abstract][Full Text] [Related]
10. Reversing of multidrug resistance breast cancer by co-delivery of P-gp siRNA and doxorubicin via folic acid-modified core-shell nanomicelles.
Wu Y; Zhang Y; Zhang W; Sun C; Wu J; Tang J
Colloids Surf B Biointerfaces; 2016 Feb; 138():60-9. PubMed ID: 26655793
[TBL] [Abstract][Full Text] [Related]
11. Co-delivery of PDTC and doxorubicin by multifunctional micellar nanoparticles to achieve active targeted drug delivery and overcome multidrug resistance.
Fan L; Li F; Zhang H; Wang Y; Cheng C; Li X; Gu CH; Yang Q; Wu H; Zhang S
Biomaterials; 2010 Jul; 31(21):5634-42. PubMed ID: 20430433
[TBL] [Abstract][Full Text] [Related]
12. Folate/N-acetyl glucosamine conjugated mesoporous silica nanoparticles for targeting breast cancer cells: A comparative study.
Kumar P; Tambe P; Paknikar KM; Gajbhiye V
Colloids Surf B Biointerfaces; 2017 Aug; 156():203-212. PubMed ID: 28531877
[TBL] [Abstract][Full Text] [Related]
13. Role of integrated cancer nanomedicine in overcoming drug resistance.
Iyer AK; Singh A; Ganta S; Amiji MM
Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
[TBL] [Abstract][Full Text] [Related]
14. In vivo distribution and antitumor activity of doxorubicin-loaded N-isopropylacrylamide-co-methacrylic acid coated mesoporous silica nanoparticles and safety evaluation.
Chen Y; Yang W; Chang B; Hu H; Fang X; Sha X
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):406-12. PubMed ID: 23816639
[TBL] [Abstract][Full Text] [Related]
15. Doxorubicin loaded silica nanorattles actively seek tumors with improved anti-tumor effects.
Gao F; Li L; Liu T; Hao N; Liu H; Tan L; Li H; Huang X; Peng B; Yan C; Yang L; Wu X; Chen D; Tang F
Nanoscale; 2012 Jun; 4(11):3365-72. PubMed ID: 22538830
[TBL] [Abstract][Full Text] [Related]
16. Reversal of multidrug resistance in vitro by co-delivery of MDR1 targeting siRNA and doxorubicin using a novel cationic poly(lactide-co-glycolide) nanoformulation.
Misra R; Das M; Sahoo BS; Sahoo SK
Int J Pharm; 2014 Nov; 475(1-2):372-84. PubMed ID: 25178825
[TBL] [Abstract][Full Text] [Related]
17. Folate-conjugated hybrid SBA-15 particles for targeted anticancer drug delivery.
Pang J; Zhao L; Zhang L; Li Z; Luan Y
J Colloid Interface Sci; 2013 Apr; 395():31-9. PubMed ID: 23312579
[TBL] [Abstract][Full Text] [Related]
18. Intracellular pH-Triggered, Targeted Drug Delivery to Cancer Cells by Multifunctional Envelope-Type Mesoporous Silica Nanocontainers.
Yang K; Luo H; Zeng M; Jiang Y; Li J; Fu X
ACS Appl Mater Interfaces; 2015 Aug; 7(31):17399-407. PubMed ID: 26196506
[TBL] [Abstract][Full Text] [Related]
19. Chitosan capped pH-responsive hollow mesoporous silica nanoparticles for targeted chemo-photo combination therapy.
Yan T; He J; Liu R; Liu Z; Cheng J
Carbohydr Polym; 2020 Mar; 231():115706. PubMed ID: 31888831
[TBL] [Abstract][Full Text] [Related]
20. In Vivo Antitumor Activity of Folate-Conjugated Cholic Acid-Polyethylenimine Micelles for the Codelivery of Doxorubicin and siRNA to Colorectal Adenocarcinomas.
Amjad MW; Amin MC; Katas H; Butt AM; Kesharwani P; Iyer AK
Mol Pharm; 2015 Dec; 12(12):4247-58. PubMed ID: 26567518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
